Project
A phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Amyloid Depleter ALXN2220 in adult participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Scheduled ยท 2024 until 2029
Ehl Niklas, Vetsch Susanne
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Scheduled
Start Date
2024
End Date
2029
Financing
Industry
Phase
III